Aclaris Therapeutics ACRS Single Reportable — General And Administrative Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aclaris Therapeutics's single reportable — general and administrative expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aclaris Therapeutics's single reportable — general and administrative expense?
- Aclaris Therapeutics (ACRS) reported single reportable — general and administrative expense of $6.74M in Q1 2026.
- How has Aclaris Therapeutics's single reportable — general and administrative expense changed year-over-year?
- Aclaris Therapeutics's single reportable — general and administrative expense increased by 9.8% year-over-year, from $6.14M to $6.74M.
- What does single reportable — general and administrative expense mean?
- Represents the overhead costs required to support the segment's operations, including executive management, legal, finance, and other administrative functions. This metric is used to evaluate the efficiency of the segment's management and its ability to control non-core operational spending. It serves as a measure of the segment's administrative burden.